EMEA-002359-PIP01-18-M05

Table of contents

Key facts

Invented name
Efluelda
Active substance
  • Split influenza virus, inactivated containing antigens equivalent to the A/H1N1-like strain
  • Split influenza virus, inactivated containing antigens equivalent to the A/H3N2-like strain
  • Split influenza virus, inactivated containing antigens equivalent to the B-like strain (Victoria lineage)
  • Split influenza virus, inactivated containing antigens equivalent to the B-like strain (Yamagata lineage)
Therapeutic area
Vaccines
Decision number
P/0219/2022
PIP number
EMEA-002359-PIP01-18-M05
Pharmaceutical form(s)
Suspension for injection
Condition(s) / indication(s)
Prevention of influenza infection
Route(s) of administration
Intramuscular use
Contact for public enquiries
Sanofi Pasteur

E-mail: contact-us@sanofi.com
Tel. +33 1 6974 5695
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating
Average
View all 2 ratings
2 ratings